Information Provided By: 
Fly News Breaks for April 20, 2017
CLVS, TSRO
Apr 20, 2017 | 07:26 EDT
Leerink analyst Seamus Fernandez lowered his price target for Tesaro (TSRO) to $158 from $186 on valuation. The analyst notes that the company announced the availability and launch of Zejula as well as pricing of $14,750/month, a 7% premium to Clovis' (CLVS) Rubraca, but he estimates an average pricing of $10,350/month given the frequency of dose reductions. Fernandez reiterates a Market Perform rating on the shares pending the results of TOPACIO and ARIEL3.
News For TSRO;CLVS From the Last 2 Days
There are no results for your query TSRO;CLVS
